SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2026)
SAB Biotherapeutics (SABS) posted Net Income towards Common Stockholders of -$18.9 million for Q1 2026, down 29.49% on a QoQ basis from -$14.6 million in Q4 2025, and down 263.09% year-over-year from $11.6 million in Q1 2025.
SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$18.9 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 263.09% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.3 million (down 64.27% YoY) and the FY2025 annual result came in at -$73.6 million, down 115.78% from the prior year.
- Net Income towards Common Stockholders was -$18.9 million for Q1 2026 at SAB Biotherapeutics, down from -$14.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $985863.0 in Q1 2022 and bottomed at -$22.9 million in Q4 2023.
- A 5-year average of -$9.2 million and a median of -$7.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 845.93% — and 2024, when it soared 50.15%.
- SAB Biotherapeutics' Net Income towards Common Stockholders stood at -$7.9 million in 2022, then slumped by 190.26% to -$22.9 million in 2023, then surged by 50.15% to -$11.4 million in 2024, then slipped by 27.88% to -$14.6 million in 2025, then retreated by 29.49% to -$18.9 million in 2026.
- Business Quant data shows SABS's Net Income towards Common Stockholders at -$18.9 million in Q1 2026, -$14.6 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -0.68 |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 205.99 Mn |
| 10 | SAB Biotherapeutics | 189.60 Mn | 189.60 Mn | - | -18.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -14.57 Mn |
| Sep 30, 2025 | -12.75 Mn |
| Jun 30, 2025 | -10.11 Mn |
| Mar 31, 2025 | -5.20 Mn |
| Dec 31, 2024 | -11.39 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.87 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -2.94 Mn |